3,6'-dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammation

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Ischemic stroke causes significant brain damage and functional deficits.
• Tumor necrosis factor-alpha (TNF) is a key mediator of this damage.
• 3,6'-dithiothalidomide (3,6'-DT), a thalidomide analog, selectively inhibits TNF synthesis.

Purpose of the Study:

• To evaluate the therapeutic potential of 3,6'-DT in a mouse model of focal ischemic stroke.
• To investigate the anti-inflammatory mechanisms underlying 3,6'-DT's neuroprotective effects.

Main Methods:

• Administered 3,6'-DT or thalidomide to mice before or after induced ischemic stroke.
• Assessed infarct volume, neuronal death, and neurological deficits.
• Analyzed inflammatory markers, immune cell infiltration, blood-brain barrier integrity, and TNF receptor signaling.

Main Results:

• 3,6'-DT administration reduced infarct volume, neuronal death, and neurological deficits when given before or shortly after stroke.
• 3,6'-DT treatment decreased expression of TNF, IL-1β, iNOS, and ICAM-1, and reduced immune cell infiltration.
• 3,6'-DT attenuated blood-brain barrier disruption by inhibiting MMP-9 and preserving occludin.
• Neuroprotection by 3,6'-DT was dependent on TNF receptor signaling.

Conclusions:

• 3,6'-DT demonstrates significant neuroprotective effects in a mouse model of ischemic stroke.
• The therapeutic benefits of 3,6'-DT are mediated by potent anti-inflammatory actions, including TNF suppression.
• 3,6'-DT represents a promising therapeutic candidate for ischemic stroke treatment.